Surgery Partners (SGRY)
(Delayed Data from NSDQ)
$33.69 USD
+5.05 (17.63%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $33.75 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.69 USD
+5.05 (17.63%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $33.75 +0.06 (0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Wall Street Analysts Predict a 35% Upside in Surgery Partners (SGRY): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 34.6% upside potential for Surgery Partners (SGRY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Surgery Partners (SGRY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ortho Clinical Diagnostics (OCDX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ortho Clinical (OCDX) delivered earnings and revenue surprises of 20% and 0.39%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Surgery Partners (SGRY) Climb 40% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.5% in Surgery Partners (SGRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Save Your Portfolio by Getting Rid of These 4 Toxic Stocks
by Rimmi Singhi
Investors who can spot the overpriced stocks and shun them at the right time are the ones likely to make a profit. SGRY, ASAI, BLKB and AZTA are a few toxic stocks that you should disown right away.
Surgery Partners (SGRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -25.00% and 0.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
Down 26.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Surgery Partners (SGRY)
by Zacks Equity Research
Surgery Partners (SGRY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Surgery Partners (SGRY) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 100.00% and -0.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -20.00% and 1.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
by Zacks Equity Research
Construction Partners, Surgery Partners, Qualcomm, AbbVie and Garmin as Zacks Bull and Bear of the Day
Bear of the Day: Surgery Partners (SGRY)
by David Bartosiak
Somebody needs to come in and give earnings a boost, stat!
Are Options Traders Betting on a Big Move in Surgery Partners (SGRY) Stock?
by Zacks Equity Research
Investors need to pay close attention to Surgery Partners (SGRY) stock based on the movements in the options market lately.
Surgery Partners (SGRY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -76.67% and 10.57%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Surgery Partners (SGRY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
by Zacks Equity Research
Zacks Industry Outlook Highlights: Medpace Holdings, AMN Healthcare Services, LHC Group and Surgery Partners
Near-Term Outlook Tepid for Medical Services Industry
by Urmimala Biswas
This sector witnesses growing demand for telemedicine-focused online medical services amid the pandemic.
Surgery Partners (SGRY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 5.88% and 1.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Surgery Partners (SGRY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 41.38% and 16.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?